PureTech Health (PRTC) notes that its Founded Entity, Seaport Therapeutics, announced topline data from portions of its ongoing Phase 1 proof-of-concept clinical trial evaluating GlyphAgo. GlyphAgo is a novel, Glyphed oral prodrug of agomelatine in development for generalized anxiety disorder and the second clinical-stage candidate from Seaport’s pipeline. Based on the data, Seaport announced plans to advance GlyphAgo into two parallel trials, a Phase 2a proof-of-pharmacology trial to evaluate the potential sleep benefit of GlyphAgo in patients with GAD and a Phase 2b randomized placebo-controlled trial in GAD that is designed to be registration-enabling. The GlyphAgo program and the underlying Glyph platform were initially advanced at PureTech, applying the Company’s strategy of identifying clinically validated pharmacology and overcoming key limitations through targeted innovation. The Glyph platform and related programs are now being advanced by PureTech’s Founded Entity, Seaport Therapeutics.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTC: